Colon Cancer

P=N/A, N=30, Enrolling by invitation, Seoul St. Mary's Hospital

P=N/A, N=51, Not yet recruiting, Matteo Clavarezza | Trial completion date: Apr 2026 --> Jul 2026 | Initiation date: Sep 2025 --> Feb 2026

Gene expression profiling demonstrated ≥ twofold changes in 51 genes, including downregulation of BAK1 and TRAF3, and upregulation of BIRC2, BIRC3, BIRC6, CASP8, TNFRSF8, TNFRSF11, and BOK. Collectively, these findings indicate that SFV exerts significant antitumor effects in colorectal cancer models and support its potential as a promising anticancer agent, warranting further mechanistic and translational investigation.

P1/2, N=14, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | N=73 --> 14 | Trial completion date: Jun 2028 --> Jun 2026 | Trial primary completion date: Feb 2027 --> Jun 2026

Although extremely rare, the possibility of isolated duodenal recurrence after surgery for colon cancer exists. With a brief review of the literature, we report here a rare recurrence case of transverse colon cancer which was discovered at 6 years postoperatively and resulted in curative resection.

Molecular diagnostics play a crucial role in guiding appropriate care and management for patients with TS. Early diagnosis, genetic testing, and preventive measures are essential for the effective management of this condition.

Subsequent testing revealed high-frequency microsatellite instability (MSI-H) in the colon cancer. These findings highlight the therapeutic potential of combined anti-PD-L1 and anti-CTLA-4 antibodies in the treatment of PD-L1-negative lung and MSI-H colorectal cancers.

P=N/A, N=100, Enrolling by invitation, Nanchang University | Trial primary completion date: May 2025 --> May 2026

The histopathological examination revealed neoplastic changes that corroborated with genomic studies. This study establishes cfDNA as a potential surrogate biomarker in chemical carcinogen induced lung and colon cancer models, supporting its utility for early detection, disease monitoring, and preclinical therapeutic assessment.

P=N/A, N=968, Not yet recruiting, The Third Xiangya Hospital, Central South University; The Third Xiangya Hospital, Central South University

P=N/A, N=2800, Not yet recruiting, Affiliated hangzhou first people's hospital, zhejiang university school of medicine; Affiliated hangzhou first people's hospital, zhejiang university

P=N/A, N=60, Not yet recruiting, Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical Co